CNS Pharmaceuticals, Inc. (CNSP)Healthcare | Biotechnology | Houston, United States | NasdaqCM
2.54 USD
-0.21
(-7.636%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.63 +0.09 (3.614%) ⇧ (April 17, 2026, 5:37 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:26 p.m. EDT
CNS Pharmaceuticals (CNSP) is currently in a highly volatile and uncertain position. The stock has been trading below its 52-week low, with a significant negative price-to-book ratio and a negative forward P/E, indicating poor fundamentals. The recent price history shows a downward trend with no clear momentum. Additionally, there are no dividend payouts, which is a red flag for income-focused investors. The forecasting model suggests a negative price movement in the short term, which makes it a risky proposition for short-term traders. Long-term investors should also be cautious due to the lack of positive fundamentals and the company's ongoing challenges. Overall, this stock is not a suitable investment at this time. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.671886 |
| MSTL | 0.700700 |
| AutoETS | 0.704430 |
| AutoARIMA | 0.704825 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 3.80 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.036 |
| Excess Kurtosis | 0.09 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.265 |
| Market Cap | 2,061,080 |
| Forward P/E | -6.51 |
| Beta | 0.49 |
| Website | https://www.cnspharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7645532 |
| Address1 | 2,100 West Loop South |
| Address2 | Suite 900 |
| All Time High | 5,121,000.0 |
| All Time Low | 2.057 |
| Ask | 3.35 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 32,510 |
| Average Daily Volume3 Month | 32,850 |
| Average Volume | 32,850 |
| Average Volume10Days | 32,510 |
| Beta | 0.489 |
| Bid | 1.98 |
| Bid Size | 2 |
| Book Value | 7.15 |
| City | Houston |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.54 |
| Current Ratio | 1.976 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.75 |
| Day Low | 2.54 |
| Debt To Equity | 7.265 |
| Display Name | CNS Pharmaceuticals |
| Earnings Timestamp End | 1,755,547,200 |
| Earnings Timestamp Start | 1,755,028,800 |
| Ebitda | -15,982,641 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.301 |
| Enterprise Value | -4,811,362 |
| Eps Forward | -0.39 |
| Eps Trailing Twelve Months | -35.75 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.8746 |
| Fifty Day Average Change | -0.33459997 |
| Fifty Day Average Change Percent | -0.1163988 |
| Fifty Two Week Change Percent | -76.45532 |
| Fifty Two Week High | 34.8 |
| Fifty Two Week High Change | -32.26 |
| Fifty Two Week High Change Percent | -0.9270115 |
| Fifty Two Week Low | 2.057 |
| Fifty Two Week Low Change | 0.48300004 |
| Fifty Two Week Low Change Percent | 0.234808 |
| Fifty Two Week Range | 2.057 - 34.8 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,573,223,400,000 |
| Float Shares | 715,828 |
| Forward Eps | -0.39 |
| Forward P E | -6.5128207 |
| Free Cashflow | -6,958,225 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00119 |
| Held Percent Institutions | 0.19031 |
| Implied Shares Outstanding | 811,449 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,753,142,400 |
| Last Split Factor | 1:12 |
| Long Business Summary | CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas. |
| Long Name | CNS Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 2,061,080 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_555951193 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -15,850,564 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,061,080 |
| Number Of Analyst Opinions | 1 |
| Open | 2.68 |
| Operating Cashflow | -13,811,107 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 800 946 9185 |
| Post Market Change | 0.091799974 |
| Post Market Change Percent | 3.6141722 |
| Post Market Price | 2.6318 |
| Post Market Time | 1,776,461,870 |
| Previous Close | 2.75 |
| Price Hint | 4 |
| Price To Book | 0.35524476 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.756 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.21000004 |
| Regular Market Change Percent | -7.6363654 |
| Regular Market Day High | 2.75 |
| Regular Market Day Low | 2.54 |
| Regular Market Day Range | 2.54 - 2.75 |
| Regular Market Open | 2.68 |
| Regular Market Previous Close | 2.75 |
| Regular Market Price | 2.54 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 25,127 |
| Return On Assets | -1.15347 |
| Return On Equity | -2.9629502 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 811,449 |
| Shares Percent Shares Out | 0.066599995 |
| Shares Short | 54,014 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 43,399 |
| Short Name | CNS Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.066599995 |
| Short Ratio | 1.17 |
| Source Interval | 15 |
| State | TX |
| Symbol | CNSP |
| Target High Price | 10.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 10.0 |
| Total Cash | 7,201,014 |
| Total Cash Per Share | 8.874 |
| Total Debt | 328,571 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -35.75 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.330025 |
| Two Hundred Day Average Change | -3.7900252 |
| Two Hundred Day Average Change Percent | -0.5987378 |
| Type Disp | Equity |
| Volume | 25,127 |
| Website | https://www.cnspharma.com |
| Zip | 77,027 |